Karen Spruyt1,2, Wiebe Braam3,4, Marcel Smits3,5, Leopold Mg Curfs3,6. 1. Governor Kremers Center-Rett Expertise Center & MHeNs, Maastricht University, Maastricht, Netherlands. spruytsleep@gmail.com. 2. Department of Developmental and Behavioral Pediatrics, Shanghai Children's Medical Center affiliated with Shanghai Jiaotong University School of Medicine, Shanghai, China. spruytsleep@gmail.com. 3. Governor Kremers Center-Rett Expertise Center & MHeNs, Maastricht University, Maastricht, Netherlands. 4. 's Heeren Loo Zuid-Veluwe, Wekerom, Netherlands. 5. Department of Neurology, Gelderse Vallei Hospital, Ede, Netherlands. 6. Department of Genetics, Maastricht University Medical Centre, Maastricht, Netherlands.
Abstract
AIMS: Individuals with Smith-Magenis syndrome (SMS) are reported to have a disrupted circadian rhythm. Our aim was to examine problematic sleeping in those attending our sleep clinic for the first time. METHODS: At intake, caregivers of 50 children and nine adults with SMS were surveyed about the sleep pattern and potential melatonin administration. Sampling of salivary melatonin levels was performed. RESULTS: At intake, exogenous melatonin was used by 16 children (27.1% of sample; 56.3% male) with mean age 6.8 ± 2.8 years, whereas 34 children (57.6%; 7.5 ± 4.8 years old; 64.7% male) and nine adults (15.3%; 36.8 ± 15.3 years old; 44.4% male) were not taking melatonin at intake. Participants were reported to have problems with night waking and early awakenings regardless of melatonin administration. Overall, moderate to high levels of salivary melatonin at noon were found in individuals with SMS. In particular, children with SMS showed a disrupted melatonin pattern. Furthermore, the endogenous melatonin level, age, and gender may potentially interact, yielding the severity range of sleep disturbances reported in SMS. CONCLUSION: Treatment of sleep problems in SMS is complex, and our findings may support person-centered sleep and medication management. Future clinical trials including larger groups may shed light on such approaches.
AIMS: Individuals with Smith-Magenis syndrome (SMS) are reported to have a disrupted circadian rhythm. Our aim was to examine problematic sleeping in those attending our sleep clinic for the first time. METHODS: At intake, caregivers of 50 children and nine adults with SMS were surveyed about the sleep pattern and potential melatonin administration. Sampling of salivary melatonin levels was performed. RESULTS: At intake, exogenous melatonin was used by 16 children (27.1% of sample; 56.3% male) with mean age 6.8 ± 2.8 years, whereas 34 children (57.6%; 7.5 ± 4.8 years old; 64.7% male) and nine adults (15.3%; 36.8 ± 15.3 years old; 44.4% male) were not taking melatonin at intake. Participants were reported to have problems with night waking and early awakenings regardless of melatonin administration. Overall, moderate to high levels of salivary melatonin at noon were found in individuals with SMS. In particular, children with SMS showed a disrupted melatonin pattern. Furthermore, the endogenous melatonin level, age, and gender may potentially interact, yielding the severity range of sleep disturbances reported in SMS. CONCLUSION: Treatment of sleep problems in SMS is complex, and our findings may support person-centered sleep and medication management. Future clinical trials including larger groups may shed light on such approaches.
Authors: Emily N C Manoogian; Lisa S Chow; Pam R Taub; Blandine Laferrère; Satchidananda Panda Journal: Endocr Rev Date: 2022-03-09 Impact factor: 25.261
Authors: Erik Boot; Cathelijne C Linders; Sterre H Tromp; Marie-José van den Boogaard; Agnies M van Eeghen Journal: Am J Med Genet A Date: 2021-06-04 Impact factor: 2.802
Authors: Christos M Polymeropoulos; Justin Brooks; Emily L Czeisler; Michaela A Fisher; Mary M Gibson; Kailey Kite; Sandra P Smieszek; Changfu Xiao; Sarah H Elsea; Gunther Birznieks; Mihael H Polymeropoulos Journal: Genet Med Date: 2021-07-27 Impact factor: 8.822